Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Drug pricing

Drug manufacturer offers to pay NHS £8m to resolve CMA allegations of anti-competitive behaviour

If the Competition and Markets Authority concludes that competition law has been broken regarding Aspen’s fludrocortisone acetate 0.1mg product, the manufacturer may have to pay a £2.1m fine.

A drug manufacturer has offered to pay the NHS £8m to resolve concerns around allegations of anti-competitive behaviour over the supply of a prescription drug.

The offer of payment from drug manufacturer Aspen, which is part of a proposed deal intended to resolve allegations against the company, is the first of its kind according to the Competition and Markets Authority (CMA).

The £8m offer comes as the CMA is continuing to investigate alleged anti-competitive arrangements concerning the company’s fludrocortisone acetate 0.1mg product, which is prescribed for the treatment of Addison’s disease, a rare adrenal insufficiency disorder.

The case hinges on allegations that Aspen entered into arrangements with two rival drug companies in 2016, paying them to stay out of the market, which then allowed the company to set its NHS price without competition.

Details of the proposed deal to resolve the case, which was drawn up after Aspen approached the CMA, are set out in the CMA’s ‘Notice of Intention to Accept Binding Commitments’, which is being consulted on until 2 September 2019.

The deal requires Aspen to admit that it was party to an illegal, anti-competitive agreement and commit to ensuring that there are at least two other UK suppliers of fludrocortisone in future.

Aspen would also have to pay a £2.1m fine if the ongoing CMA investigation concludes that competition law has been broken.

Andrea Coscelli, chief executive of the CMA, said: “The £8m Aspen has agreed to provide will save the NHS the time and expense of seeking damages in court.

“Importantly, Aspen has also committed to ensuring there are more competitors in this market, giving the NHS the opportunity to secure better value for UK taxpayers’ money in the future.”

The CMA is continuing to investigate the two other companies suspected of illegally participating in the arrangement.

A statement from Aspen said that offering the funds “does not consititue an admission of any wrongdoing”, adding that it had admitted liability for breaching Article 101 of the Treaty of the Functioning of the EU by “entering into an agreement to acquire a potential competitor Fludrocortisone with the consequence that the conclusion of this agreement resulted in anti-competitive behaviour”. 

It added: “The commitments offered by Aspen and the settlement discussions being undertaken between the CMA and Aspen reflect the group’s willingness to address the concerns raised by competition authorities into alleged anti-competitive conduct by Aspen. The group remains committed to the resolution of other outstanding investigations in the interest of patients.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20206955

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Physicochemical Principles of Pharmacy

    Physicochemical Principles of Pharmacy

    This established textbook covers every aspect of drug properties from the design of dosage forms to their delivery by all routes to sites of action in the body.

    £48.00Buy now
  • Prescribing Medicines for Children

    Prescribing Medicines for Children

    Prescribing Medicines for Children is designed to improve understanding on all aspects of paediatric prescribing, from the development of suitable drugs through to their practical administration.

    £60.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • FASTtrack: Pharmacology

    FASTtrack: Pharmacology

    FASTtrack: Pharmacology is a study guide providing an account of drug action, as well as dealing with molecular pharmacology at a more advanced level.

    £25.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.